ApoB
For informational purposes only — not medical advice. Always consult a qualified healthcare provider before making changes to your health regimen. Full disclaimer →
- ApoB is a better predictor of cardiovascular risk than LDL-C — it counts the actual particles, not just the cholesterol they carry.
- Longevity-optimal target: below 60 mg/dL. Standard labs flag anything below 100–130 mg/dL as acceptable — that threshold is designed to detect disease, not optimize lifespan.
- ApoB is not in a standard lipid panel. You need to specifically request it or use a longevity-focused testing service.
- Statins, PCSK9 inhibitors, diet, and exercise all lower ApoB — often dramatically. This is one of the most actionable longevity markers you can test.
- Test every 3 months while actively intervening; every 6–12 months once stable below target.
Why ApoB Is the Gold Standard for Cardiovascular Risk
For decades, LDL cholesterol (LDL-C) was the primary tool for assessing heart disease risk. It's still the most commonly ordered lipid marker. But LDL-C has a fundamental limitation: it measures the amount of cholesterol carried inside LDL particles, not the number of particles themselves.
This matters because particle size varies. A person with many small, dense LDL particles might have the same LDL-C reading as someone with fewer, larger particles — but dramatically different cardiovascular risk. The small-particle person has more particles circulating, more opportunities for those particles to penetrate artery walls and initiate the atherosclerotic process.
ApoB solves this. Because every atherogenic particle — LDL, VLDL, IDL, and Lp(a) — carries exactly one ApoB protein on its surface, ApoB is a direct particle count. Higher ApoB means more particles. More particles means more risk. The relationship is linear and robust across large population studies.
A landmark 2021 analysis published in the European Heart Journal found that ApoB was superior to LDL-C and non-HDL cholesterol as a predictor of cardiovascular events across a range of populations and risk categories. The authors concluded that ApoB should be the primary lipid measurement in clinical practice. 1
Standard Reference Ranges vs. Longevity-Optimal Ranges
Standard clinical reference ranges for ApoB are designed to identify patients at high near-term cardiovascular risk. They are not designed to optimize for a long healthspan. The gap between "clinically normal" and "longevity-optimal" is significant.
| Category | ApoB Level | Standard Interpretation | Longevity Assessment |
|---|---|---|---|
| Longevity-optimal | Below 60 mg/dL | Below normal range | Optimal — minimum atherosclerotic burden |
| Good | 60–80 mg/dL | Within normal range | Good — continue monitoring |
| Monitor | 80–100 mg/dL | Normal / borderline | Monitor — consider intervention |
| Elevated | 100–130 mg/dL | Borderline high / high | Elevated — intervention recommended |
| High | Above 130 mg/dL | High risk | High — aggressive intervention needed |
The longevity-optimal target of below 60 mg/dL is informed by studies of populations with naturally low lifetime ApoB levels — including certain hunter-gatherer societies and populations in rural China and Africa — who show near-zero rates of atherosclerotic heart disease well into old age. 2
Dr. Peter Attia, arguably the most influential voice in longevity medicine, publicly targets an ApoB of 60 mg/dL or below for his patients, and uses this as a primary metric for cardiovascular longevity optimization. Many patients require pharmacological intervention to reach this level — and he considers that a reasonable tradeoff given the stakes.
Already have your lab results? See how your ApoB and other markers score on a longevity scale — in under 60 seconds.
Analyze My Biomarkers →What Drives ApoB Up — and Down
ApoB is not fixed. It is highly responsive to diet, lifestyle, body composition, and medication. Understanding the levers is what makes it one of the most actionable longevity biomarkers.
Factors that raise ApoB
- High intake of saturated and trans fats — stimulates LDL particle production in the liver
- Excess refined carbohydrates and added sugar — drives VLDL production, which converts to LDL
- Insulin resistance and metabolic syndrome — impairs LDL clearance from the bloodstream
- Hypothyroidism — reduces LDL receptor activity, reducing particle clearance
- Familial hypercholesterolemia — genetic condition that can drive ApoB to very high levels regardless of lifestyle
- Obesity — particularly visceral adiposity increases VLDL and LDL particle production
Factors that lower ApoB
- Statins — reduce hepatic cholesterol synthesis, upregulating LDL receptors; typically lower ApoB by 30–50%
- PCSK9 inhibitors — block the protein that degrades LDL receptors; can lower ApoB by 50–70% on top of statin therapy
- Replacing saturated fat with unsaturated fats — reduces LDL particle production
- Soluble fiber (oats, legumes, psyllium) — binds bile acids in the gut, forcing the liver to convert more cholesterol to bile, reducing LDL
- Aerobic exercise — improves insulin sensitivity, reduces VLDL production, raises HDL
- Weight loss — reducing visceral fat directly lowers VLDL and LDL particle production
ApoB vs. LDL-C vs. Non-HDL Cholesterol
When you get a standard lipid panel, you receive LDL cholesterol (LDL-C) and non-HDL cholesterol figures. How do these compare to ApoB as risk predictors?
LDL-C measures cholesterol mass inside LDL particles. It does not account for particle number, and can meaningfully underestimate risk in people with high particle counts and small particle sizes — a pattern common in metabolic syndrome, insulin resistance, or high triglycerides.
Non-HDL cholesterol (total cholesterol minus HDL) is a modest improvement because it captures cholesterol in VLDL and IDL particles in addition to LDL. But it still measures cholesterol mass, not particle number.
ApoB directly counts all atherogenic particles. In head-to-head analyses, ApoB is a consistently superior predictor of cardiovascular events compared to both LDL-C and non-HDL cholesterol, particularly in people with metabolic syndrome, elevated triglycerides, or type 2 diabetes. 3
The practical implication: if your LDL-C looks reasonable but your triglycerides are elevated and your HDL is low, your ApoB may be telling a very different story. Always test it directly.
How to Test ApoB
ApoB is a simple blood test that requires a standard blood draw. It is not included in a standard lipid panel — you need to request it specifically. Here are the most reliable options:
Through a longevity testing service: Function Health, InsideTracker, and Marek Health all include ApoB in their comprehensive panels alongside 40–100+ other longevity markers. This is the highest-value approach for anyone building a longevity biomarker baseline.
À la carte through Ulta Lab Tests: If you only need ApoB — or want to retest a specific marker without ordering a full panel — Ulta Lab Tests allows you to order without a doctor's visit and delivers results in 24–48 hours at most US locations. Cost is typically $25–40.
Through your physician: Any primary care physician can order ApoB. However, many will not unless you specifically request it, as it is not part of standard annual screening. Some insurance plans cover it with cardiovascular risk justification.
How Often Should You Test?
If your ApoB is above 80 mg/dL and you are actively making dietary, lifestyle, or pharmacological changes, test every 90 days to measure response. Lipid markers respond to interventions within this timeframe, and regular feedback is the mechanism that keeps interventions on track.
Once you've achieved and maintained a level below 60 mg/dL for two consecutive tests, testing every 6–12 months is sufficient to confirm stability. Always pair ApoB with a full lipid panel and an inflammatory marker like hsCRP to get the complete cardiovascular picture.
Sources
- Johannesen CDL, et al. "Apolipoprotein B and Non-HDL Cholesterol Better Reflect Residual Risk Than LDL Cholesterol in Statin-Treated Patients." European Heart Journal, 2021. PubMed →
- O'Keefe JH, et al. "Optimal Low-Density Lipoprotein Is 50 to 70 mg/dl." Journal of the American College of Cardiology, 2004. PubMed →
- Sniderman AD, et al. "A Meta-Analysis of Low-Density Lipoprotein Cholesterol, Non-High-Density Lipoprotein Cholesterol, and Apolipoprotein B as Markers of Cardiovascular Risk." Circulation: Cardiovascular Quality and Outcomes, 2011. PubMed →
| Range Type | Value (mg/dL) | Notes |
|---|---|---|
| Standard Clinical Range | < 100 mg/dL | Designed to identify disease risk — not longevity optimisation. |
| Longevity-Optimal Target | < 60 mg/dL |
Associated with reduced all-cause mortality and extended healthspan.
Target used by longevity medicine physicians including Dr. Peter Attia, based on populations with naturally low lifetime ApoB who show near-zero atherosclerotic disease rates.
|
Already have your results? See what your ApoB and other markers reveal about your longevity in 60 seconds.
Analyze My Labs →Affiliate disclosure: we may earn a commission if you purchase through these links at no extra cost to you.
What is a good ApoB level for longevity?
For longevity optimization, the target ApoB is below 60 mg/dL. This is more aggressive than standard clinical guidelines, which flag levels above 100–130 mg/dL as acceptable. The longevity medicine community targets below 60 mg/dL based on data from populations with naturally low lifetime ApoB exposure who show near-zero rates of atherosclerotic disease.
Why is ApoB better than LDL cholesterol?
LDL cholesterol measures the amount of cholesterol carried inside LDL particles, not the number of particles. ApoB directly counts the atherogenic particles — each LDL, VLDL, and IDL particle carries exactly one ApoB protein. Two people can have identical LDL-C values but very different particle counts and therefore very different cardiovascular risk. ApoB captures this distinction; LDL-C does not.
How do you lower ApoB naturally?
The most effective lifestyle interventions for lowering ApoB are reducing refined carbohydrates and added sugars, replacing saturated fat with mono- and polyunsaturated fats, increasing soluble fiber intake (oats, legumes, psyllium husk), achieving a healthy body weight, and regular aerobic exercise. For many people, statins or PCSK9 inhibitors are also required to reach longevity-optimal levels below 60 mg/dL.
Does a standard blood test include ApoB?
No. ApoB is not included in a standard lipid panel. You need to specifically request it, or order it through a direct-to-consumer lab service. It is included in comprehensive longevity panels from Function Health, InsideTracker, and Marek Health, and can be ordered à la carte from Ulta Lab Tests for approximately $25–40.
How often should I test ApoB?
If your ApoB is above the longevity-optimal range and you are actively intervening through diet, exercise, or medication, retest every 3 months to track the response. Once you've reached and stabilized below 60 mg/dL, testing every 6–12 months is sufficient. Always test ApoB alongside other lipid markers and hsCRP for a complete cardiovascular risk picture.